Product Images Rosuvastatin Calcium

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 5 images provide visual information about the product associated with Rosuvastatin Calcium NDC 50090-6735 by A-s Medication Solutions, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

fig-1 - fig 1

fig-1 - fig 1

fig-2 - fig 2

fig-2 - fig 2

Number of events: End point Roswva20mg Placebo2omg HR(95%Ch Pvalue (n=8901) (n=8901) Hazard Ratio (—95%—) nrate*) n(rate*) Primary end point (MCE) 142(7.6) 252(136) 056(046,060) <0.001 - Cardiovascular death* 3509 44(24) 0.80(051,1.24) 0315 e Nonfatal Stroke 3001.6) 58(31) 052(033,080) 0.003 —— Nonfatal MI 2202 62(33) 035(022,058 <0001 e Hospitalized 16(09) 27015 059(032,1.10) 0,093 — unstable Angina < Arterial 71(38) RETAM] 054(0.41,072) <0.001 - revascularization 10 * eventrate/1000-patient years ** Cardiovascular death induded fatal M, fatal stroke, sudden death, and other adjudicated causes of CV death Description: This text seems to contain data related to a medical study or clinical trial. It includes the number of events observed for different endpoints, such as cardiovascular death, nonfatal stroke, nonfatal MI (myocardial infarction), hospitalized unstable angina, and arterial revascularization. The table also provides information on the medication and placebo groups, including the hazard ratio and p-values.*

fig-3 - fig 3

fig-3 - fig 3

Label Image - lbl500906735

Label Image - lbl500906735

rosuva-structure - rosuva structure

rosuva-structure - rosuva structure

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.